These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16109077)

  • 1. Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients.
    Chan D; Irish A; Dogra G
    Nephrology (Carlton); 2005 Aug; 10(4):336-40. PubMed ID: 16109077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
    Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
    J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of low-dose i.v. iron therapy in haemodialysis patients.
    Park J; Chang JW; Lee JS; Chung HC; Yang WS; Lee SK; Park SK; Park JS
    Nephrology (Carlton); 2009 Dec; 14(8):716-21. PubMed ID: 20025679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload.
    Tarng DC; Huang TP
    Nephrol Dial Transplant; 1998 Nov; 13(11):2867-72. PubMed ID: 9829492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
    Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
    Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial.
    Auerbach M; Ballard H; Trout JR; McIlwain M; Ackerman A; Bahrain H; Balan S; Barker L; Rana J
    J Clin Oncol; 2004 Apr; 22(7):1301-7. PubMed ID: 15051778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia.
    Tarng DC; Wei YH; Huang TP; Kuo BI; Yang WC
    Kidney Int; 1999 Jun; 55(6):2477-86. PubMed ID: 10354297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial hematologic effects of daily oral ascorbic acid therapy in ESRD patients with anemia and abnormal iron homeostasis: a preliminary study.
    Sirover WD; Siddiqui AA; Benz RL
    Ren Fail; 2008; 30(9):884-9. PubMed ID: 18925528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients.
    Reuter SE; Faull RJ; Ranieri E; Evans AM
    Nephrol Dial Transplant; 2009 Mar; 24(3):990-6. PubMed ID: 18987259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
    Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
    Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of reticulocyte haemoglobin content as marker of iron deficiency and predictor of response to intravenous iron in haemodialysis patients.
    Kim JM; Ihm CH; Kim HJ
    Int J Lab Hematol; 2008 Feb; 30(1):46-52. PubMed ID: 18190467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin.
    Aggarwal HK; Nand N; Singh S; Singh M; Hemant ; Kaushik G
    J Assoc Physicians India; 2003 Feb; 51():170-4. PubMed ID: 12725261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
    Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
    Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of intravenous iron therapy for HCV-positive haemodialysis patients.
    Kahraman S; Yilmaz R; Genctoy G; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
    Nephron Clin Pract; 2005; 100(3):c78-85. PubMed ID: 15824511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
    Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
    Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
    Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.